Mapping Genes for Atherosclerosis and Insulin Resistance

绘制动脉粥样硬化和胰岛素抵抗基因图谱

基本信息

  • 批准号:
    7848277
  • 负责人:
  • 金额:
    $ 73.87万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-06-01 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) is the largest cause of morbidity and mortality in the Western world. New risk factors for CVD include insulin resistance (IR) and chronic inflammation. The hypothesis of this proposal and its linked Progression R01 is that genetic factors are in significant measure responsible for the interrelationship between CVD, IR and inflammation, and that these can be identified by family studies utilizing high definition phenotyping of subclinical pathophysiologic processes, such as euglycemic clamp for IR and carotid intima-medial thickness (CIMT) by ultrasound for CVD, in a Mexican-American population at high risk for these disorders. In our prior work, we studied a large Mexican-American cohort, ascertained through an index case with coronary artery disease (CAD). Genome scans in the first half of this sample (Set 1) identified evidence for chromosomal loci for CIMT, for fasting insulin, and for IR. Aim 1 will confirm these loci by analysis of a genome wide scan in the second half of the sample (Set 2); followed by fine mapping with the goal of prioritizing the best peaks, between two and three, for use in Aim 2. Aim 2 will test all the genes under the "best" linkage peaks from Aim 1, taking advantage of growing resources that allow identification of tagged SNPs. This approach simultaneously avoids the limitation of trying to a priori decide what genes are true positional candidates, and yet by focusing on genes, is more efficient than a chromosomal marker approach. All genes under each peak will be tested in Set 1. Positive results will be confirmed using Set 2 and only those genes still positive will be evaluated further in Aim 4. This two-stage design provides the power to identify the relevant genes while minimizing false positives. In Aim 3, 20 biologic candidate genes identified as associated with IR, fasting insulin, or CIMT in Set 1, either during the first cycle of the Program (n=13) or suggested by the linked Progression R01 (n=7) (and tested in Set 1), will be tested in Set 2 to confirm the associations and prioritize the genes for study in Aim 4. These genes will have their haplotypes characterized in detail for testing in Set 2. In Aim 4, genes (from Aims 2 and 3) associated with CIMT, fasting insulin, and/or IR in Set 1 and confirmed in Set 2, will be sequenced in individuals with divergent haplotypes and phenotypes. New variants discovered by sequencing will be genotyped in the entire study population to assess the minimum variant(s) within each gene that appear responsible for the genetic effect. Gene-gene interactions will also be evaluated. A key strength of this proposal is that the size of the sample allows replication (Set 1 and Set 2) of both linkage and association results in the same population, with the same ethnicity, same ascertainment, and the same phenotyping. Identifying the genes for CIMT and IR in this understudied population will provide new tools for risk assessment and prevention.
描述(由申请人提供):心血管疾病(CVD)是西方世界发病率和死亡率的最大原因。心血管疾病的新危险因素包括胰岛素抵抗(IR)和慢性炎症。该提议及其相关进展R 01的假设是,遗传因素在很大程度上负责CVD、IR和炎症之间的相互关系,并且这些可以通过利用亚临床病理生理过程的高清晰度表型的家族研究来鉴定,例如IR的正葡萄糖钳夹和CVD的超声颈动脉内膜中层厚度(CIMT),在这些疾病的高风险墨西哥裔美国人群体中。在我们之前的工作中,我们研究了一个大型的墨西哥裔美国人队列,通过冠状动脉疾病(CAD)的索引病例确定。该样本的前半部分(第1组)的基因组扫描鉴定了CIMT、空腹胰岛素和IR的染色体基因座的证据。目标1将通过分析样本的后半部分(第2组)的全基因组扫描来确认这些基因座;然后进行精细定位,目标是优先选择两个和三个之间的最佳峰,用于目标2。目标2将测试目标1中“最佳”连锁峰下的所有基因,利用不断增长的资源来识别标记的SNP。这种方法同时避免了试图先验决定哪些基因是真正的位置候选者的限制,并且通过关注基因,比染色体标记方法更有效。将在第1组中检测每个峰下的所有基因。将使用第2组确认阳性结果,仅在目标4中进一步评价仍为阳性的基因。这种两阶段设计提供了识别相关基因的能力,同时最大限度地减少假阳性。在目标3中,将在第2组中测试在计划的第一个周期期间(n=13)或由关联进展R 01(n=7)建议(并在第1组中测试)的第1组中被鉴定为与IR、空腹胰岛素或CIMT相关的20个生物学候选基因,以确认相关性并优先考虑用于目标4中研究的基因。这些基因的单倍型将在第2组中进行详细表征。在目标4中,将在具有不同单倍型和表型的个体中对与第1组中的CIMT、空腹胰岛素和/或IR相关并在第2组中确认的基因(来自目标2和3)进行测序。通过测序发现的新变异将在整个研究人群中进行基因分型,以评估每个基因中似乎导致遗传效应的最小变异。还将评价基因-基因相互作用。这个建议的一个关键优势是样本的大小允许在相同的人群中复制(第1组和第2组)连锁和关联结果,具有相同的种族,相同的确定和相同的表型。在这个研究不足的人群中识别CIMT和IR的基因将为风险评估和预防提供新的工具。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A novel method for testing association of multiple genetic markers with a multinomial trait.
一种测试多个遗传标记与多项性状关联的新方法。
A Multinomial Ordinal Probit Model with Singular Value Decomposition Method for a Multinomial Trait.
多项性状的奇异值分解方法的多项序概率模型。
  • DOI:
    10.1155/2012/419832
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    1.1
  • 作者:
    Kwon,Soonil;Goodarzi,MarkO;Taylor,KentD;Cui,Jinrui;Chen,Y-DIda;Rotter,JeromeI;Hsueh,Willa;Guo,Xiuqing
  • 通讯作者:
    Guo,Xiuqing
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jerome I Rotter其他文献

URIDINE MONOPHOSPHATE KINASE: A NEW GENETIC MARKER OF SUSCEPTIBILITY TO HAEMOPHILUS INFLUENZAE TYPE B DISEASE: 158
尿苷单磷酸激酶:B 型流感嗜血杆菌疾病易感性的新遗传标记:158
  • DOI:
    10.1203/00006450-198507000-00178
  • 发表时间:
    1985-07-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Gloria M Petersen;Diana R Silimperi;Edward M Scott;David R Hall;Jerome I Rotter;Joel I Ward
  • 通讯作者:
    Joel I Ward
701 CHROMOSOMAL VARIANTS IN HABITUAL ABORTION
习惯性流产中的 701 种染色体变异
  • DOI:
    10.1203/00006450-198104001-00724
  • 发表时间:
    1981-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Bruce D Blumberg;Jeffery D Shulkin;Jerome I Rotter;T K Mohandas;Michael M Kaback
  • 通讯作者:
    Michael M Kaback

Jerome I Rotter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jerome I Rotter', 18)}}的其他基金

xADAGES III: Contribution of genotype to glaucoma phenotype in African Americans
xADAGES III:基因型对非裔美国人青光眼表型的贡献
  • 批准号:
    9127971
  • 财政年份:
    2013
  • 资助金额:
    $ 73.87万
  • 项目类别:
xADAGES III: Contribution of genotype to glaucoma phenotype in African Americans
xADAGES III:基因型对非裔美国人青光眼表型的贡献
  • 批准号:
    8559980
  • 财政年份:
    2013
  • 资助金额:
    $ 73.87万
  • 项目类别:
xADAGES III: Contribution of genotype to glaucoma phenotype in African Americans
xADAGES III:基因型对非裔美国人青光眼表型的贡献
  • 批准号:
    8915183
  • 财政年份:
    2013
  • 资助金额:
    $ 73.87万
  • 项目类别:
Mapping Genes for Atherosclerosis and Insulin Resistance
绘制动脉粥样硬化和胰岛素抵抗基因图谱
  • 批准号:
    7434575
  • 财政年份:
    2007
  • 资助金额:
    $ 73.87万
  • 项目类别:
Mapping Genes for Atherosclerosis and Insulin Resistance
绘制动脉粥样硬化和胰岛素抵抗基因图谱
  • 批准号:
    7249179
  • 财政年份:
    2007
  • 资助金额:
    $ 73.87万
  • 项目类别:
GENE APPROACH TO IMMUNOPHENOTYPIC SUBGROUPS OF CROHN'S DISEASE
克罗恩病免疫表型亚群的基因方法
  • 批准号:
    7487325
  • 财政年份:
    2007
  • 资助金额:
    $ 73.87万
  • 项目类别:
Mapping Genes for Atherosclerosis and Insulin Resistance
绘制动脉粥样硬化和胰岛素抵抗基因图谱
  • 批准号:
    7624596
  • 财政年份:
    2007
  • 资助金额:
    $ 73.87万
  • 项目类别:
GENES AS IMMUNOPHENOTYPIC SUBGROUPS OF CROHN'S DISEASE
基因作为克罗恩病的免疫表型亚群
  • 批准号:
    7024923
  • 财政年份:
    2005
  • 资助金额:
    $ 73.87万
  • 项目类别:
Genetics of Diabetic Retinopathy in Hispanics
西班牙裔糖尿病视网膜病变的遗传学
  • 批准号:
    7995175
  • 财政年份:
    2004
  • 资助金额:
    $ 73.87万
  • 项目类别:
Genetics of Diabetic Retinopathy in Hispanics
西班牙裔糖尿病视网膜病变的遗传学
  • 批准号:
    7909498
  • 财政年份:
    2004
  • 资助金额:
    $ 73.87万
  • 项目类别:

相似海外基金

Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
  • 批准号:
    2867610
  • 财政年份:
    2023
  • 资助金额:
    $ 73.87万
  • 项目类别:
    Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
  • 批准号:
    BB/W009633/1
  • 财政年份:
    2022
  • 资助金额:
    $ 73.87万
  • 项目类别:
    Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2021
  • 资助金额:
    $ 73.87万
  • 项目类别:
    Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
  • 批准号:
    459043
  • 财政年份:
    2021
  • 资助金额:
    $ 73.87万
  • 项目类别:
    Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2020
  • 资助金额:
    $ 73.87万
  • 项目类别:
    Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10561642
  • 财政年份:
    2019
  • 资助金额:
    $ 73.87万
  • 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2019
  • 资助金额:
    $ 73.87万
  • 项目类别:
    Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
  • 批准号:
    2243045
  • 财政年份:
    2019
  • 资助金额:
    $ 73.87万
  • 项目类别:
    Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10359032
  • 财政年份:
    2019
  • 资助金额:
    $ 73.87万
  • 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
  • 批准号:
    428988
  • 财政年份:
    2019
  • 资助金额:
    $ 73.87万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了